
NYMX on NASDAQ | Today's Change | Volume | 52 Week Range (Low/Hi) | Market Cap |
2.53US | 0% | 146,254 | 1.6600 - 4.7900 | 195.344M |
Contact Information
Nymox Pharmaceutical Corporation
Headquarters:9900 Cavendish Boulevard,
Saint-Laurent, Québec
Canada, H4M 2V2
Tel: 800-936-9669
Fax: 514-332-2227
Email: Send a message
Website: Visit website
For more information...
Lead: Robert ThaemlitzMedia: D. Elizabeth Culley-Sullo
Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.
Paul Averback, MD, DABP - President and CEO
Erik Danielsen - Chief Financial Officer
Randall Lanham - Independent Director
Suresh Kalbag, MD - Director
James G. Robinson - Director
Professor David Morse - Director
Richard Cutler - Director

Stock Information
Press Releases
Company Overview
Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.
Management
Paul Averback, MD, DABP - President and CEO
Erik Danielsen - Chief Financial Officer
Board of Directors
Randall Lanham - Independent Director
Suresh Kalbag, MD - Director
James G. Robinson - Director
Professor David Morse - Director
Richard Cutler - Director
Contact Information
9900 Cavendish Boulevard,
Saint-Laurent, Québec
H4M 2V2, Canada
Telephone: 800-936-9669
Fax: 514-332-2227
Email: Send a message
Website: Visit website